Medable Archives - Medical Design Sourcing

Medable and CVS Health partner to expand clinical trial access

Medable and CVS Health (NYSE:CVS) announced yesterday that they will collaborate to expand clinical trial access and engagement.

Under the collaboration, Medable’s software platform will be combined with CVS Health’s community reach and experienced MinuteClinic providers to deliver clinical trials in a manner that improves patient access, engagement and retention. According to a news release, CVS Health Clinical Trial Services will manage the relationship.

Medable designed its digital platform to streamline design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution.

“Our mission is to bring effective therapies to all patients, regardless of where they live, their social status or race. This collaboration intends to bridge research and science into communities with local access and experience that builds greater trust in hea…

Decentralized clinical trials can have big financial upside, study finds

Televisit image courtesy of Medable

The use of decentralized clinical trials (DCTs) exploded during the pandemic, but quantifying their financial benefits has been elusive.

Medable (Palo Alto, California), the maker of a cloud-based DCT platform, has announced that DCTs can accelerate clinical trial timelines and lead to significant cost savings.

Medable and its research partner, the Tufts Center for the Study of Drug Development (CSDD), found that for Phase 2 studies, a standard DCT deployment yielded a one-to-three month time savings over a traditional Phase 2 study. In addition, a DCT yielded a financial benefit that is up to five times more than the upfront investment.

Time savings for Phase 3 studies were similar, while the net financial benefit was up to 14 times more than the upfront investment.

To learn more about the recent research, we spoke with Dr. Pamela Tenaerts, chief s…

Medable’s CSO opens up on rethinking clinical drug development

Direct-to-patient clinical trial company Medable (Palo Alto, California) has recently hired MaryAnne Rizk as its chief strategy officer. Rizk was IQVIA’s former senior vice president, digital R&D strategy.

Rizk was also recently named a PharmaVoice 100 leader.

Rizk is also a graduate advisor and an adjunct professor for the school of engineering at the Stevens Institute of Technology (Hoboken, New Jersey), where she founded the Pharmaceutical Alumni Association and earned a doctorate in technology management, systems engineering.

In the following Q&A, Rizk touches on what inspired her to join Medable, her core goals and what inspires her.

Drug Discovery & Development: What inspired you to join Medable?

Rizk: I came home. Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies, which aligns with my mission. Medable’s culture truly aligns with …

Medable installs new chief strategy officer

Direct-to-patient clinical trial company Medable (Palo Alto, California) has added MaryAnne Rizk to its executive team.

Rizk formerly worked at IQVIA as a senior vice president, digital R&D strategy. She is also an adjunct professor at the Steven Institute of Technology (Hoboken, New Jersey) and a managing partner at Rizk Management Consulting.

In August, Rizk was named a PharmaVoice 100 leader.

She is also a member of the Healthcare Businesswomen’s Association, Prix Galien Foundation Digital Advisory Board and Society for Clinical Research Sites (SCRS) Innovation Council.

The startup Medable has continued to grow rapidly during the pandemic, scoring another $78 million in funding to help it continue advancing clients’ digital and decentralized clinical trials.

In her role at Medable, Rizk will work to bolster the company’s strategic partnerships and innovation ecosystem.

She will also endeavor to improve clinical trial diversi…

The top digital health startups in the world

About two-fifths of the startups in CB Insights’ second annual Digital Health 150 list are engaged in telehealth, a high-demand area amid the COVID-19 pandemic.

That is one of the big takeaways from the list of 150 promising digital health startups that CB Insights released today. CB Insights’ research team picked the 150 startups after using the company’s platform to evaluate nearly 8,000 startups on factors including patent activity, business relations, investor profile, news sentiment analysis, proprietary Mosaic scores, market potential, competitive landscape, team strength and tech novelty. (Download the full report here.)

The 62 telehealth startups on the list include telemedicine platforms such as cardiology platform Heartbeat Health (New York), virtual visit platform Doctor On Demand (San Francisco), and Livi medical app creator KRY (Stockholm, Sweden). There are remote monitoring and diagnostics companies including Oura (Oulu, Finland…